Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

December 7, 2017

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Published on 12/06/2017

previous post: US oncologists, unfamiliar with MACRA, are not implementing it
next post: Neurostimulant use is associated with improved survival in comatose patients after cardiac arrest regardless of electroencephalographic substrate